Seborrheic Dermatitis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Seborrheic dermatitis is a common skin illness that causes a red, scaly, itchy rash on the head, sides of the nose, brows, and between the brows, ears, eyelids, and the middle of the chest. Other areas that may be affected include the belly button, buttocks, armpits, breasts, and groin. Seborrheic dermatitis can be chronic. It tends to clear and flare up without warning. Treatment is frequently required to keep it under control. Seborrheic dermatitis clears up on its own for some people. Seborrheic dermatitis affects people of all ages. It occurs most often in infants, older adults, and men than women.

The incidence cases range from 3 to 7 percent of the adult population in the world.

 

The competitive landscape of Seborrheic Dermatitis includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Seborrheic Dermatitis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Seborrheic Dermatitis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Seborrheic Dermatitis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Roflumilast foam Or roflumilast cream    Arcutis Biotherapeutics, Inc.       Phase 3

2          Azelaic Acid (AzA) 15% Gel       LEO Pharma     Phase 2

3          Omiganan         Maruho Co., Ltd.           Phase 2

4          PAC-14028 cream         Amorepacific Corporation           Phase 2

5          Clobetasol Propionate 0.05% Shampoo  Galderma R&D  Phase 3

6          Elidel    Novartis            Phase 2

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Familial Chylomicronemia Syndrome (FCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by mutations in the lipoprotein lipase gene, leading to hypertriglyceridemia and chylomicron accumulation in plasma. High triglycerides can result in complications like acute pancreatitis. FCS is also known as Lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, and Endogenous hypertriglyceridemia. Diagnosis is based on fasting triglyceride levels exceeding 750 mg/dL and can be confirmed through genetic testing. Symptoms can emerge in infancy, childhood, or adolescence, with some patients remaining asymptomatic until adulthood. Common signs include Lipemia Retinalis (milky appearance in retinal veins), eruptive xanthomas (skin bumps with fatty deposits), abdominal pain, milky blood, and pancreatitis. Repeated pancreatitis is a severe complication that can lead to long-term pancreatic dysfunction and potential fatality if left untreated. FCS patients face a higher risk of pancreatiti...
Read more